Clinical Trial Update: A Study to Evaluate Next Day Effects of MK-4305 on Driving Performance (MK-4305-035 AM1) [Phase 1]

View source ↗

Summary

A Phase 1 study to evaluate the next-day driving performance effects of MK-4305 in insomnia; the trial has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Insomnia

Drugs mentioned

• MK-4305

Snippet

Sponsor: Merck Sharp & Dohme LLC | Conditions: Insomnia | Phase 1 | Status: COMPLETED